CSF3 and systemic sclerosis: These data support overall insufficient vasculogenesis to counterbalance vascular damage and might suggest the mobilization of EPCs from the bone marrow (for example, with administration of G-CSF, statins, or erythropoietin) as a potential target for future therapies in SSc, especially in patients with the late-NVC pattern [33-35].